Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium

被引:54
作者
Miller, Benjamin Ray [1 ]
Bezprozvanny, Ilya [1 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA
关键词
apoptosis n calcium n cortex; dopamine; electrophysiology; glutamate n Huntexil r; Huntington's disease; medium spiny neuron; neurodegeneration; striatum n tetrabenazine;
D O I
10.2217/FNL.10.41
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Huntington's disease (HD) is a noncurable and progressive autosomal-dominant neurodegenerative disorder that results from a polyglutamine expansion in the amino-terminal region of the huntingtin protein. The generation of rodent HD models has revealed that cellular dysfunction, rather than cell death alone, occurs early in the disease progression, appearing even before overt symptom onset. Much evidence has now established that dysfunction of the corticostriatal circuit is key to HD symptomology. In this article, we summarize the most current findings that implicate glutamate, dopamine and calcium signaling in this system and discuss how they work in concert to disrupt corticostriatal function. In addition, we highlight therapeutic strategies related to altered corticostriatal signaling in HD.
引用
收藏
页码:735 / 756
页数:22
相关论文
共 209 条
  • [1] THE FUNCTIONAL-ANATOMY OF BASAL GANGLIA DISORDERS
    ALBIN, RL
    YOUNG, AB
    PENNEY, JB
    [J]. TRENDS IN NEUROSCIENCES, 1989, 12 (10) : 366 - 375
  • [2] Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease
    Ali, Noore J.
    Levine, Michael S.
    [J]. DEVELOPMENTAL NEUROSCIENCE, 2006, 28 (03) : 230 - 238
  • [3] Dopamine and Glutamate in Huntington's Disease: A Balancing Act
    Andre, Veronique M.
    Cepeda, Carlos
    Levine, Michael S.
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (03) : 163 - 178
  • [4] Altered cortical glutamate receptor function in the r6/2 model of Huntington's disease
    André, VM
    Cepeda, C
    Venegas, A
    Gomez, Y
    Levine, MS
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 2006, 95 (04) : 2108 - 2119
  • [5] Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy
    Arai, Tetsuaki
    Hasegawa, Masato
    Nonoka, Takashi
    Kametani, Fuyuki
    Yamashita, Makiko
    Hosokawa, Masato
    Niizato, Kazuhiro
    Tsuchiya, Kuniaki
    Kobayashi, Zen
    Ikeda, Kenji
    Yoshida, Mari
    Onaya, Mitsumoto
    Fujishiro, Hiroshige
    Akiyama, Haruhiko
    [J]. NEUROPATHOLOGY, 2010, 30 (02) : 170 - 181
  • [6] Striatal neurochemical changes in transgenic models of Huntington's disease
    Ariano, MA
    Aronin, N
    Difiglia, M
    Tagle, DA
    Sibley, DR
    Leavitt, BR
    Hayden, MR
    Levine, MS
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) : 716 - 729
  • [7] Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - An in situ hybridization study
    Arzberger, T
    Krampfl, K
    Leimgruber, S
    Weindl, A
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (04) : 440 - 454
  • [8] Bachurin S, 2001, ANN NY ACAD SCI, V939, P425
  • [9] Mitochondria as a target for neurotoxins and neuroprotective agents
    Bachurin, SO
    Shevtsova, EP
    Kireeva, EG
    Oxenkrug, GF
    Sablin, SO
    [J]. NEUROPROTECTIVE AGENTS, 2003, 993 : 334 - 344
  • [10] Dopamine modulates release from corticostriatal terminals
    Bamford, NS
    Robinson, S
    Palmiter, RD
    Joyce, JA
    Moore, C
    Meshul, CK
    [J]. JOURNAL OF NEUROSCIENCE, 2004, 24 (43) : 9541 - 9552